CD19 and myasthenia gravis: In MG patients with acute aggravation, we observed that the TRAF6 levels in CD19+ B cells were upregulated in GMG compared with OMG, suggesting that the TRAF6 levels in CD19+ B cells are relevant to MG phenotypes and may be a useful biomarker of disease subtype.